Australia's most trusted
source of pharma news
Posted 15 July 2025 AM
AbbVie has put $2.9 billion on the table for the next step in multiple myeloma treatment, a first-in-class tri-specific asset in Phase 1 trials, that could outdo rivals Pfizer and Johnson & Johnson in the same space.
The licensing deal with IGI Therapeutics, a wholly owned subsidiary of NASDAQ-listed Indian company Ichnos Glenmark Innovation, gives AbbVie exclusive rights to develop, manufacture, and commercialise IGI's lead investigational asset, ISB 2001, across North America, Europe, Japan, and Greater China.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.